Pipeline
Advancing toward clinical development.
Inicure's lead compounds are in the preclinical stage, moving along a clear trajectory toward first-in-human studies.
Discovery
CompletedDiscovery: CompletedEarly preclinical
OngoingEarly preclinical: OngoingLate preclinical
Not startedLate preclinical: Not startedPhase 1
Not startedPhase 1: Not startedPhase 2 - Topical use
Not startedPhase 2 - Topical use: Not startedPhase 2 - Systemic use
Not startedPhase 2 - Systemic use: Not startedFPR1 agonists
Discovery
Completed
Discovery: CompletedEarly preclinical
Ongoing
Early preclinical: OngoingLate preclinical
Not started
Late preclinical: Not startedPhase 1
Not started
Phase 1: Not startedPhase 2 - Topical use
Not started
Phase 2 - Topical use: Not startedPhase 2 - Systemic use
Not started
Phase 2 - Systemic use: Not started
Completed
Discovery
Identification and characterisation of patent-protected small molecule FPR1 agonists activating the innate immune system.
Ongoing
Early preclinical
Efficacy in infection models, formulation work for topical and systemic use, and early safety profiling of lead compounds.
Not started
Late preclinical
Candidate selection, regulatory toxicology and CMC work required to enter first-in-human studies.
Not started
Phase 1
First-in-human evaluation of safety, tolerability and pharmacokinetics.
Not started
Phase 2 - Topical use
Clinical evaluation of efficacy following topical application in indications such as infected wounds and burns.
Not started
Phase 2 - Systemic use
Clinical evaluation of efficacy in systemic indications, including urinary tract infections (UTIs), pyelonephritis, and pulmonary infections.
All data described is from preclinical studies.